Advertisement

Topics

Clovis Oncology Announces 2016 Operating Results

16:05 EST 22 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Rubraca™ (rucaparib) approved and launched in the U.S. on December 19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer $266.2M in cash, cash equivalents and available for sale securities ...

Other Sources for this Article

Clovis Oncology, Inc.
Breanna Burkart, 303-625-5023
bburkart@clovisoncology.com
or
Anna Sussman, 303-625-5022
asussman@clovisoncology.com

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology Announces 2016 Operating Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...